-
Stocks rise, yields ease as oil slips on Trump hint at short bombing campaign
-
Hamilton hopes to boost title bid with record Italian triumph
-
Brussels Diamond League finals Day 1 - five events to watch
-
Iran, US trade threats after fresh strikes
-
Thailand's 'Jurassic Park' shines light on dinosaur evolution
-
US not 'stealing Venezuelan oil,' energy secretary insists
-
'Role model' Stokes set to open for Adelaide Strikers
-
Farming experts tout 'conscious' food systems to fix agriculture woes
-
Palau urges 'unified' Pacific response to China missile test
-
George Lucas unveils art galaxy at his new LA museum
-
Grinding away: in remote Appalachia, old mills fuel US clean food dreams
-
Veteran Wallaby Slipper targets fifth World Cup after Brumbies deal
-
Sabalenka races into US Open third round
-
Sabalenka storms into US Open third round as Pegula, Medvedev advance
-
Chinese lucky loser stuns Jodar at US Open
-
Zverev looks to improve after first-round scare
-
US Open under the influence: content creators spark debate
-
Raiders to start Cousins over top NFL Draft pick Mendoza
-
NBA hammers Clippers over Leonard salary cap violations
-
Palantir chief says France's digital sovereignty push 'backfiring'
-
NBA strips five first-round draft picks from Clippers for Leonard salary cap violations
-
US energy firms dominate Venezuela deals worth billions
-
Kane brace helps Bayern win German Cup opener
-
Iran, US trade threats after escalation in fighting
-
Migrant plight, local anger divide Ceuta one month after influx
-
US jury deadlocks again in Lindsay Clancy's child murder trial
-
Outrage as Maltese tycoon acquitted of reporter's murder
-
Lake America? No way, Canadians say
-
Rare train of Pacific cyclones fueled by historic El Nino
-
Spain report flags Moroccan police failings in Ceuta migrant rush
-
Macron, King Charles hail UK-France ties after viewing Bayeux Tapestry
-
Tech bosses press G20 to build data centers, but split on risk
-
Fury hits out at 'coward' Joshua as 'Battle of Britain' talks go on
-
Dolly Parton to get new Hollywood star after vandalism
-
Maltese tycoon acquitted of masterminding reporter's murder
-
Trump 'happy' Prince Harry and Meghan have left US
-
George Clooney: a Hollywood icon and campaigner
-
Michelson shocks Nakashima in US Open clash of rising Americans
-
Europe, US closer than they look on tech rules, says EU tech chief
-
Another body recovered after ferry capsizes off northern Cyprus: official
-
Clooney honoured as Hollywood-light Venice Film Festival kicks off
-
Cupertino Chamber President Claudio Bono Invited to White House with GiveaRoof 3-Year Plan to End Homelessness
-
Third-ranked Pegula, Medvedev power into US Open third round
-
Trump floats renaming Strait of Hormuz as 'Trump Strait'
-
Davis-Woodhall a doubt for Ultimate Championship after car crash
-
Man City, Chelsea fuel record-breaking Premier League transfer window
-
Third-ranked Pegula powers into US Open third round
-
Balogun rejected Everton move over transfer 'treatment'
-
Uber says laying off 'about 10%' of workforce worldwide
-
Northampton seek 'happy medium' in bid to keep England star Pollock
Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month
Bausch Health's gastroenterology business, Salix Pharmaceuticals, recognizes the complexities of irritable bowel syndrome (IBS) and seeks to make a difference in how the condition is perceived, diagnosed and treated.
LAVAL, QC / ACCESS Newswire / April 2, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the launch of IBS Symptoms Aren't Black and White: Living in the Gray, an authentic storytelling campaign that addresses the complexities of living with irritable bowel syndrome (IBS). Throughout April, which is IBS Awareness Month, Salix will be sharing patient stories on LinkedIn, highlighting the unique journeys of individuals living with IBS.
Irritable bowel syndrome is more than just a common condition that affects up to an estimated 10% of the global population - it is a complex condition with unpredictable symptoms that can impact every aspect of patients' lives, including one's physical, emotional, social and professional well-being.1,2 Navigating the road to proper care can be a long and complicated process; Salix seeks to bring greater understanding to help improve how IBS is perceived, diagnosed and treated.
"We recognize that every patient's experience is unique and has the potential to inspire others in the IBS community to seek the care they deserve," said Nicola Kayel, Senior Vice President, Marketing, Salix. "Our campaign, IBS Symptoms Aren't Black & White: Living in the Gray, underscores our ongoing commitment to supporting patients by amplifying their voices to raise visibility, build a community of empowered individuals and destigmatize the narrative that surrounds this condition."
Many people with IBS agree that their symptoms, such as diarrhea and hard to pass bowel movements, can be hard to talk about, and as a result, unresolved symptoms cause the burden of IBS to persist.2 Patient advocacy group, the International Foundation for Gastrointestinal Disorders (IFFGD), recognizes this obstacle and is partnering with Salix to generate conversation and share authentic stories. By normalizing open and honest discussions about IBS and reducing stigma, Salix and IFFGD hope to motivate patients to talk to their healthcare providers about the full range of their IBS symptoms, including less obvious experiences like abdominal pain, bloating and urgency.
President of IFFGD, Ceciel T. Rooker, stated, "At IFFGD, we are committed to broadening patient understanding of GI disorders like IBS. We are proud to support Salix in their effort to illuminate real patient stories to help raise visibility of the authentic patient experience and the multi-faceted nature of IBS symptoms. We believe it will encourage patients to speak up about their symptoms and ultimately receive appropriate care for their condition."
Click here to read about real patients' experiences on Salix Pharmaceuticals' LinkedIn.
##
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our gastroenterology business, Salix Pharmaceuticals, is one of the largest specialty pharmaceutical businesses in the world and has licensed, developed and marketed innovative products for the treatment of gastrointestinal diseases for more than 30 years. For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.
References
Mayo Clinic. (2023). Irritable Bowel Syndrome (IBS). Retrieved from https://www.mayoclinic.org/diseases-conditions/irritable-bowel-syndrome/symptoms-causes/syc-20360016
International Foundation for Functional Gastrointestinal Disorders (IFFGD). (2024) IBS Facts and Statistics. AboutIBS.org. https://aboutibs.org/what-is-ibs/facts-about-ibs/.
©2025 Salix Pharmaceuticals or its affiliates.
Investor Contact: | Media Contact: |
SOURCE: Bausch Health Companies Inc.
View the original press release on ACCESS Newswire
B.Torres--AT